Allarity Therapeutics A/S
(ALLR)

Allarity Therapeutics A/S

18:00:00 · First North Sweden

18:00:00 · Valuta i SEK

First North Sweden

Senast

0,940

Idag %

+6,82%

Idag +/-

+0,060

Köp

0,940

Sälj

0,940

Högst

0,992

Lägst

0,800

Omsatt (Antal)

8 989 325

18:00:00 · First North Sweden

18:00:00 · Valuta i SEK

First North Sweden

Allarity Therapeutics A/S

18:00:00 · First North Sweden · Valuta i SEK

18:00:00 · Valuta i SEK

First North Sweden

Senast

0,940

Utveckling idag

+6,82%

+0,060

Köp

0,940

Sälj

0,940

Högst

0,992

Lägst

0,800

Omsatt (Antal)

8 989 325

Utveckling

Visa volym

Orderdjup

Ingen data hittades

Senaste avslut

Tid	Pris	Antal	Köpare	Säljare
-		-	-	-

Volymvägt snittpris (VWAP)

0,883

VWAP

0,883

Omsättning (SEK)

7 946 104

Mäklarstatistik

Ingen data hittades

Företagshändelser

Det finns inga angivna utdelningar

Nyheter & Analyser

Utveckling

Visa volym

Inga Nordnet Markets Certifikat finns med underliggande värdepapper.

Nyheter & Analyser

Företagshändelser

Det finns inga angivna utdelningar

Orderdjup

Ingen data hittades

Senaste avslut

Tid	Pris	Antal	Köpare	Säljare
-		-	-	-

Volymvägt snittpris (VWAP)

0,883

VWAP

0,883

Omsättning (SEK)

7 946 104

Mäklarstatistik

Ingen data hittades

Företagshändelser

Det finns inga angivna utdelningar

*Kommentarerna ovan kommer från shareville.se och har varken redigerats eller granskats av Nordnet. De innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna.

Nyckeldata

P/E
-
P/E*
-
P/B
-
P/S
-
Utdelning/aktie
-
EPS
-
Direktavkastning
-
EPS tillväxt*
-
PEG
-

*Baserat på estimat

Finansiell översikt

Morningstar faktablad

Resultaträkning ()

category_local

Balansräkning ()

category_local

Kassaflöde ()

category_local

Bolagsöversikt

Företagsnamn	-
VD	-
E-post	-
Hemsida	-
Säte	-
Antal anställda	-
Antal aktier	-
Börsvärde	-

Om värdepapperet

Namn	Allarity Therapeutics A/S
ISIN	-
Sektor	-
Bransch	-
Kortnamn	ALLR
Introduktionsdatum	-
Belåningsgrad	0%
Säkerhetskrav	200%

SwedenAllarity Therapeutics A/S(ALLR)

SwedenAllarity Therapeutics A/S(ALLR)

SwedenAllarity Therapeutics A/S

SwedenAllarity Therapeutics A/S

SwedenAllarity Therapeutics A/S

SwedenAllarity Therapeutics A/S

Start of Volatility Halt Auction Period: Order book 'ALLR' in market 'First North STO' at 16:57:17.718

Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus

Start of Volatility Halt Auction Period: Order book 'ALLR' in market 'First North STO' at 15:59:31.381

Allarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus

Allarity Therapeutics issues new shares to Aalto Capital in connection with services rendered

Allarity Therapeutics Draws Down the Third Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

2020 in Review: A Letter from Allarity’s CEO

Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses

Allarity Therapeutics (ALLR): A new direction and name for Oncology Venture

Mest handlade

Start of Volatility Halt Auction Period: Order book 'ALLR' in market 'First North STO' at 16:57:17.718

Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus

Start of Volatility Halt Auction Period: Order book 'ALLR' in market 'First North STO' at 15:59:31.381

Allarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus

Allarity Therapeutics issues new shares to Aalto Capital in connection with services rendered

Allarity Therapeutics Draws Down the Third Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

2020 in Review: A Letter from Allarity’s CEO

Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses

Allarity Therapeutics (ALLR): A new direction and name for Oncology Venture

Start of Volatility Halt Auction Period: Order book 'ALLR' in market 'First North STO' at 16:57:17.718

Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus

Start of Volatility Halt Auction Period: Order book 'ALLR' in market 'First North STO' at 15:59:31.381

Allarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus

Allarity Therapeutics issues new shares to Aalto Capital in connection with services rendered

Allarity Therapeutics Draws Down the Third Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

2020 in Review: A Letter from Allarity’s CEO

Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses

Allarity Therapeutics (ALLR): A new direction and name for Oncology Venture

Resultaträkning ()

Balansräkning ()

Kassaflöde ()

Om värdepapperet

Allarity Therapeutics A/S
(ALLR)